Since pS6 levels do not change after APD treatment (figure 3), the downregulation of PBMC mTORC1/S6K activity in FEP patients probably represents a signaling endophenotype which is stable, unlike the case of pGSK3β, and perhaps is associated with the pathophysiology of schizophrenia. Here, RPS6KB1 is linked to schizophrenia.